PepGen climbs 100% as BofA upgrades on new mid-stage trial data for lead asset
FROM THE WIRE · SEEKINGALPHA.COM
[Currency-US Dollar Up] ModernLife PepGen (PEPG [https://seekingalpha.com/symbol/PEPG]) climbed more than 100% on Tuesday as Bank of America upgraded the company following additional data from a mid-stage trial for its lead asset, PGN-EDODM1, in myotonic dystrophy type 1, a rare…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA major bank upgrade backed by new clinical data drove a sharp rally in this small-cap biotech.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01PepGen shares climbed more than 100% on Tuesday.
- 02Bank of America upgraded the company after new Phase 2 data for PGN-EDODM1.
- 03Mean splicing correction reached 46.5% at Week 13 versus 6.8% for placebo.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets